7th Mar 2016 08:27
LONDON (Alliance News) - AstraZeneca PLC on Monday said its biologics research and development arm MedImmune received a fast track designation from the US Food and Drug Administration for MEDI8852 for the treatment of patients with Type A strain influenza.
The designation is designed to speed up the development and review of drugs that address serious conditions and fill an unmet medical need.
The drug is currently being evaluation in a phase Ib/II a clinical trial, and recently completed a phase I study which showed it has an acceptable safety and pharmacokinetics profile.
Shares in AstraZeneca were trading down 0.4% at 4,007.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca